Clinical Trial

Diagnostic and Prognostic Value of Reticulated Platelet Fraction in Ventilator-Associated Pneumonia (REPLAY-VAP)

Study acronym: REPLAY-VAP
Completed
View on ClinicalTrials.gov →
Summary
Ventilator-associated pneumonia (VAP) is a serious infection that occurs in patients who have been on mechanical ventilation for more than 48 hours in the intensive care unit (ICU). Early and accurate diagnosis is critical to reduce complications and improve outcomes. This prospective observational study aims to evaluate the diagnostic and prognostic value of reticulated platelet fraction (RP%) in patients diagnosed with VAP. Blood samples will be taken as part of routine care, and RP% levels will be analyzed using a standard hematology analyzer. The study will investigate whether RP% can help identify VAP earlier and predict outcomes such as mortality and response to antibiotics.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-06-02; most recent amendment 2026-05-12.
Status change: Recruiting → Completed 2026-05-12
Status change: Not Yet Recruiting → Recruiting 2025-12-08
Trial Details
NCT Number NCT07013032
Lead Sponsor Konya City Hospital
Conditions Ventilator-Associated Pneumonia
Enrollment 41 participants
Start Date 2025-07-01
Primary Completion 2026-05-12 (estimated)
Study Completion 2026-05-12 (estimated)
Updated on ClinicalTrials.gov 2026-05-13